init.bio
Oliver Zill is the Founder and Principal at init.bio, providing scientific strategy and operations in computational biology for life sciences product development since August 2021. Previously, Oliver served as VP of Computational Biology at ImmuneBridge, where responsibilities included building teams, developing AI/ML algorithms, and leading fundraising efforts. Prior experiences include roles as Senior Scientist and Group Leader at Genentech, Bioinformatics Scientist at Guardant Health, and various research positions at UCSF, the University of Washington, UC Berkeley, and NYU Langone Medical Center. Academic credentials include a Ph.D. in Molecular Biology from the University of California, Berkeley, and a B.A. in Biology from Columbia University.
This person is not in the org chart
This person is not in any teams
init.bio
init.bio partners with biotech founders and leaders on a consulting basis to help drive scientific strategy and operations. We cater to your needs and can work with you as strategic scientific advisors or fractional operators to help you accelerate and derisk product development at your company. We are experienced wet lab & computational scientists who have successfully taken drugs and diagnostics into the clinic by building high-performing computational biology teams, designing and executing efficient data analysis workflows, and standing up state-of-the-art AI models and high-throughput screens. Core areas of expertise span bioinformatics/computational biology, genomics, oncology, immunology, diagnostics and therapeutics product development, and other R&D areas. Examples of technical services we provide include: - Establishing cloud computing infrastructure & single-cell sequencing analysis workflows for drug target identification. - Designing & executing experimental strategies to validate cell therapy platforms for immuno-oncology. - Leveraging large ‘omics data sets and advanced analytics for biomarker analysis, patient selection, and clinical development planning for therapeutics assets. - Standing up computer-aided drug design workflows, including AI/ML models, for small molecule drug discovery. Examples of advisory & managerial services we provide include: - Building high-performing computational biology teams (contractor and/or FTE) that follow best practices for collaborative development. - Establishing academic and CRO partnerships to obtain patient samples and validate target discovery platforms. - Advising on platform approach and data packages for potential partnerships with pharma companies Our primary goal is to set you up for long-term success through a combination of common sense, robust scientific and engineering practices, and capital-efficient approaches.